

1 KRISTY M. AREVALO, State Bar No. 216308
kma@mccunewright.com
2 TUAN Q. NGUYEN, State Bar No. 312513
tqn@mccunewright.com
3 MCCUNE WRIGHT AREVALO, LLP
3281 East Guasti Road, Suite 100
4 Ontario, California 91761
Telephone: (909) 557-1250
5 Facsimile: (909) 557-1275

6 *Attorneys for Plaintiff*
7

8 UNITED STATES DISTRICT COURT
9 FOR THE CENTRAL DISTRICT OF CALIFORNIA

10
11 JOYCE ULRICH,

12 Plaintiff,

13 v.

14 HOWMEDICA OSTEONICS CORP.,
15 STRYKER ORTHOPAEDICS, a New
Jersey Corporation; STRYKER
16 CORPORATION, a Michigan
Corporation; and DOES 1-10, inclusive,

17 Defendants.
18
19
20
21
22

Case No.:

COMPLAINT FOR MONEY DAMAGES

- 1) Negligence;
- 2) Strict Products Liability (Manufacturing Defect);
- 3) Strict Products Liability (Design Defect);
- 4) Strict Products Liability (Inadequate Warning);
- 5) Strict Products Liability (Failure to Conform to Representations);
- 6) Strict Products Liability (Failure to Adequately Test);
- 7) Breach of Express Warranty;
- 8) Breach of Implied Warranty of Merchantability;
- 9) Negligent Misrepresentation;
- 10) Fraud; and
- 11) Punitive Damages

DEMAND FOR JURY TRIAL

TABLE OF CONTENTS

1		
2		Page(s)
3	I. INTRODUCTION	1
4	II. PARTIES	1
5	III. JURISDICTION AND VENUE.....	3
6	IV. FACTUAL BACKGROUND.....	3
7	A. Total Hip Arthroplasty Procedure	3
8	B. FDA Process.....	4
9	C. The Accolade TMZF® Hip Stem and LFIT™ Anatomic V40™ Femoral	
10	Head.....	6
11	D. Defendants’ Defective Products.....	7
12	E. Defendants’ LFIT™ Anatomic V40™ Femoral Head Recall	9
13	F. Plaintiff Joyce Ulrich’s Experience Illustrates a Tragic But Not Uncommon	
14	or Unforeseeable Risk Associated with Defendants’ Defective Devices	10
15	V. CAUSES OF ACTION.....	13
16	FIRST CAUSE OF ACTION – NEGLIGENCE	13
17	SECOND CAUSE OF ACTION – STRICT PRODUCTS LIABILITY	
18	(MANUFACTURING DEFECT)	15
19	THIRD CAUSE OF ACTION – STRICT PRODUCTS LIABILITY (DESIGN	
20	DEFECT)	15
21	FOURTH CAUSE OF ACTION – STRICT PRODUCTS LIABILITY	
22	(INADEQUATE WARNING)	16
23	FIFTH CAUSE OF ACTION – STRICT PRODUCTS LIABILITY (FAILURE TO	
24	CONFORM TO REPRESENTATIONS).....	17
25	SIXTH CAUSE OF ACTION – STRICT PRODUCTS LIABILITY (FAILURE	
26	TO ADEQUATELY TEST).....	17
27	SEVENTH CAUSE OF ACTION – BREACH OF EXPRESS WARRANTY.....	18
28		

1 EIGHTH CAUSE OF ACTION – BREACH OF IMPLIED WARRANTY OF
2 MERCHANTABILITY 19
3 NINTH CAUSE OF ACTION – NEGLIGENT MISREPRESENTATION 20
4 TENTH CAUSE OF ACTION – FRAUD 21
5 ELEVENTH CAUSE OF ACTION – PUNITIVE DAMAGES 22
6 VI. PRAYER FOR RELIEF 22
7 VII. DEMAND FOR JURY TRIAL 23
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 Plaintiff Joyce Ulrich (“Plaintiff”) alleges on information and belief, by and
2 through her undersigned attorneys, against Defendants Howmedica Osteonics Corp.,
3 Stryker Orthopaedics, a New Jersey Corporation, Stryker Corporation, a Michigan
4 Corporation, and DOES 1-10 Inclusive, (collectively “Defendants”), the following:

5 **I. INTRODUCTION**

6 1. This is an action for damages suffered by Plaintiff Joyce Ulrich, as a direct
7 and proximate result of Defendants’ wrongful conduct in connection with developing,
8 designing, testing, assembling, manufacturing, packaging, labeling, preparing,
9 distribution, marketing, supplying, and/or selling the Accolade TMZF[®] Hip Stem
10 (“Accolade Hip Stem”) and the LFIT[™] Anatomic V40[™] Femoral Head (“LFIT Femoral
11 Head”), (hereinafter collectively “Defective Devices.”)

12 2. Defendants knew or should have known that the Defective Devices
13 implanted in Plaintiff can cause fretting and corrosion at the junction between the femoral
14 stem and the femoral head. Fretting and corrosion is known by Defendants to cause
15 personal injury, significant pain, disability, dislocation, and loss of movement, and these
16 injuries can only be partially remedied through revision surgeries.

17 3. Defendants mislead healthcare professionals and the public into believing its
18 femoral hip stem was safe and effective for use in total hip arthroplasty procedures;
19 engaged in deceptive, misleading and unconscionable promotional or sales methods to
20 convince healthcare professionals to utilize Defendants’ femoral hip stem, even though
21 Defendants knew or should have known its femoral hip stem was unreasonably
22 dangerous; and failed to warn healthcare professionals and the public about the safety
23 risk of its femoral hip stem, including Plaintiff and her physicians.

24 **II. PARTIES**

25 4. Plaintiff Joyce Ulrich is, and at all times relevant to this Complaint was, a
26 resident of Rancho Mirage, California, County of Riverside.

27 5. Defendant Stryker Orthopaedics is, and at all times relevant to this
28 Complaint was, a New Jersey Corporation with its principle place of business at 325

1 Corporate Drive, Mahwah, NJ 07430. Defendant Howmedica Osteonics Corp. is, and
2 was at all times relevant herein, doing business in and/or having directed its activities in
3 California, specifically this judicial district. Defendant Howmedica Osteonics Corp. is a
4 wholly owned subsidiary of parent corporation, Stryker Corporation.

5 6. Defendant Stryker Corporation is the parent corporation organized and
6 existing under the laws of Michigan, with its principal place of business in Kalamazoo,
7 Michigan. Defendant Howmedica Osteonics Corp., is, and was at all times relevant
8 herein, doing business in and/or having directed its activities in California, specifically
9 this judicial district. Defendant Stryker Corporation is a medical technology company
10 creating orthopedic implants as well as medical and surgical equipment to healthcare
11 professionals.

12 7. Plaintiff is unaware of the true names and capacities, whether individual,
13 corporate, associate, or otherwise, of Defendants DOES 1-10, inclusive, or any of them,
14 and therefore sues these Defendants, and each of them, by such fictitious names. Plaintiff
15 will seek leave of this Court to amend this Complaint when the status and identities of
16 these Defendants are ascertained.

17 8. Upon information and belief, at all times relevant herein, the employees of
18 Defendants, their subsidiaries, affiliates, and other related entities were the agents,
19 servants, and employees of Defendants, and were acting within the purpose and scope of
20 said agency and employment. Whenever referenced in this Complaint is made to any act
21 or transaction of Defendants, such designation shall be deemed to mean that the
22 principals, officers, employees, agents and/or representatives of the Defendants
23 committed, knew of, performed, authorized, ratified and/or directed such transactions on
24 behalf of Defendants while actively engaged in the scope of their duties.

25 ///

26 ///

27 ///

28 ///

1 **III. JURISDICTION AND VENUE**

2 9. This Court has diversity jurisdiction over the parties pursuant to 28 U.S.C.
3 §1332(a). Plaintiff and Defendants are citizens of different states, and the amount in
4 controversy exceeds \$75,000, exclusive of interest and costs.

5 10. This Court has in personam jurisdiction pursuant to 28 U.S.C. §1391
6 because Defendants conducted substantial business within the State of California and had
7 continuous and systematic contacts with the State of California, and they have consented
8 to jurisdiction in this state. Upon information and belief, Defendants also advertised in
9 this district, made material omissions and representations in this district, and breached
10 warranties in this district.

11 11. Venue is proper in the Central District of California pursuant to 28 U.S.C.
12 § 1391(a) and (b) because a substantial part of the events, acts and omissions giving rise
13 to these claims occurred in the Central District of California.

14 **IV. FACTUAL BACKGROUND**

15 **A. Total Hip Arthroplasty Procedure**

16 12. The Accolade[®] TMZF[®] Hip Stem and LFIT[™] Anatomic V40[™] Femoral
17 Head devices were developed in order to reconstruct human hip joints that are diseased
18 due to conditions such as osteoarthritis, rheumatoid arthritis, avascular necrosis, or
19 fracture. The hip joint connects the thigh (femur) bone of a patient's leg to the patient's
20 pelvis. The hip joint is similar to a ball that fits in a socket. The socket portion of the hip
21 is called the acetabulum. The femoral head at the top of the femur bone rotates within the
22 curved surface of the acetabulum.

23 13. A total hip replacement typically consists of four separate components: (1) a
24 femoral stem; (2) a femoral head; (3) an acetabular liner; and (4) an acetabular shell.
25 After the surgeon hollows out a patient's femur bone, the metal femoral stem is
26 implanted. The femoral head, usually manufactured from metal or ceramic, is fixed on
27 the top of the femoral stem. The femoral head forms the hip joint that can rotate when it
28 is placed inside a plastic or ceramic acetabular liner attached to the interior portion of the

1 metal acetabular shell comprised of metal on its outer surface. When the surgery is
2 complete, the femoral stem anchors the femoral head that rotates within the acetabular
3 liner sitting inside the acetabular shell.

4 14. A hip replacement system containing a metal femoral stem and a metal
5 femoral head, such as the hip replacement system implanted in Plaintiff, is known to
6 cause fretting, corrosion, and can generate particulate debris at the modular junction
7 between the stem and the head. Fretting and corrosive debris in a joint area can lead to
8 multiple complications, including but not limited to, pain, adverse local tissue reaction,
9 pseudotumors, osteolysis and/or spontaneous dissociation—fracture of the femoral neck
10 or trunnion of the prosthesis.

11 15. Failure of a hip replacement system at the junction between the stem and the
12 femoral head requires the patient to undergo subsequent revision surgery to replace the
13 failed hip replacement system.

14 **B. FDA Process**

15 16. The Medical Device Amendments to the Food, Drug, and Cosmetics Act of
16 1938 (“MDA”), in theory, requires Class II medical devices, including the Accolade Hip
17 Stem and LFIT Femoral Head, to undergo premarket approval by the FDA, a process
18 which obligates the manufacturer to design and implement a clinical investigation and
19 then submit the results of that investigation to the FDA.

20 17. Premarket approval is a rigorous process that requires a manufacturer to
21 submit what is typically a multivolume application that includes, among other things, full
22 reports of all studies and investigations of the device’s safety and effectiveness that have
23 been published or should reasonably be known to the applicant; a full statement of the
24 device’s components, ingredients, and properties and of the principle or principles of
25 operation; a full description of the methods used in, and the facilities and controls used
26 for, the manufacture, processing, and, when relevant, packing and installation of, such
27 device; samples or device components required by the FDA; and a specimen of the
28 proposed labeling.

1 18. The FDA may grant premarket approval only if it finds that there is
2 reasonable assurance that the medical devices is safe and effective and must weigh any
3 probable benefit to health from the use of the device against any probable risk of injury or
4 illness from such use.

5 19. A medical device on the market prior to the effective date of the MDA—a
6 so-called “grandfathered” device—was not required to undergo pre-market approval. In
7 addition, a medical device marketed after the MDA’s effective date may bypass the
8 rigorous premarket approval process if the device is “substantially equivalent” to a
9 “grandfathered” pre-MDA device (i.e., a device approved prior to May 28, 1976). This
10 exception to premarket approval is known as the “510(k)” process and simply requires
11 the manufacturer to notify the FDA under section 510(k) of the MDA of its intent to
12 market a device at least 90 days prior to the device’s introduction on the market, and to
13 explain the device’s substantial equivalence to a pre-MDA predicate device. The FDA
14 may then approve the new device for sale in the United States.

15 20. Through the 510(k) clearance process, a product will be cleared if the
16 manufacturer establishes that the new device is substantially equivalent to a predicate
17 device; one that is already on the market.

18 21. Rather than being approved for use by the FDA pursuant to the rigorous
19 premarket approval process, Defendants’ Defective Devices were sold on the basis that,
20 under section 510(k) of the MDA, they were “substantially equivalent” to older hip
21 implant devices that Defendants sold and implanted prior to the enactment of the MDA in
22 1976.

23 22. As such, Defendants were able to market the Defective Devices with
24 virtually no clinical or non-clinical trials or FDA review of the implants for safety and
25 effectiveness.

26 23. The Accolade Hip Stem, LFIT Femoral Head, and related components were
27 approved under the Food and Drug Administration 510(k) process. A 510(k) medical
28

1 device does not have to go through the rigors of a clinical study to gain approval by the
2 FDA.

3 24. On information and belief, Defendants did not conduct a clinical trial of the
4 Accolade system before putting it into the stream of commerce.

5 **C. The Accolade TMZF[®] Hip Stem and LFIT[™] Anatomic V40[™] Femoral Head**

6 25. At all times material hereto, Defendants developed, tested, assembled,
7 manufactured, packaged, labeled, prepared, distributed, marketed, supplied, and/or sold
8 the Defective Devices, Accolade Hip Stem and LFIT Femoral Head, either directly or
9 indirectly, to members of the general public within the state of California, including
10 Plaintiff Joyce Ulrich.

11 26. On or around March 16, 2000, Defendants received FDA clearance to sell its
12 Accolade Hip Stem in the United States. Then, on or around April 11, 2001, Defendants
13 received FDA clearance to sell its LFIT Femoral Head. These clearances were both
14 obtained through the 510(k) process.

15 27. The Accolade Hip Stem is a hip replacement prosthesis. The stem is
16 manufactured utilizing a proprietary titanium alloy consisting of titanium, molybdenum,
17 zinc, and iron. It combines the material characteristics of TMZF[®] alloy (Ti-12Mo-6Zr-
18 2Fe) and is also coated in a CP Titanium plasma sprayed coating and PureFix[™] HA. It is
19 a single piece artificial hip replacement device that is designed to be implanted into the
20 patient's femur. It is indicated for patients requiring total hip arthroplasty or replacement
21 due to joint disease.

22 28. Defendants claim in their promotional materials for the Accolade Hip Stem
23 that their alloy is both stronger and less rigid than other titanium alloys. Defendants
24 utilized print, television, internet, and/or e-mail marketing to disseminate information
25 promoting purported advantages of their Accolade Hip Stem and LFIT Femoral Heads.
26 They also claimed that the particular titanium alloy has been tested and proven to resist
27 the effects of corrosion and fretting.

28

1 29. Upon information and belief, Defendants have since abandoned the use of
2 TMZF titanium throughout its product line. Instead, Defendants now utilize a different
3 titanium alloy.

4 30. On or around November 16, 1999, and again on April 11, 2001, Defendants
5 received clearance from the FDA to market the LFIT Femoral Head.

6 31. The LFIT Femoral Head is one of the modular balls or heads designed to be
7 used with the Accolade Hip Stem and is made from a chromium/cobalt alloy.

8 32. The Accolade Hip Stem and the LFIT Femoral Head are commonly used
9 together during total hip replacement arthroplasty surgery.

10 **D. Defendants' Defective Products**

11 33. Defendants claimed that laboratory testing demonstrates the compatibility of
12 these materials without concern for fretting and corrosion. In their marketing and sale of
13 the devices, Defendants represented and warranted that proprietary materials alleviate
14 concerns for this problem. Despite Defendants' claims, the Defective Devices have been
15 reported to cause corrosion issues.

16 34. Had Defendants conducted clinical trials of the Defective Devices before
17 they were first released on the market, they would have discovered at that time what they
18 ultimately learned before and/or around August 2016—that the Defective Devices result
19 in a high percentage of patients developing trunnionosis, osteolysis, bone loss, metallosis,
20 biologic toxicity and an early and high failure rate due to the release of metal particles in
21 the patient's surrounding tissue when the cobalt-chromium metal femoral head rotates
22 within the cobalt-chromium metal acetabular liner.

23 35. In other words, implantation of the Defective Devices result in the nearly
24 immediate systemic release of high levels of toxic metal cobalt-chromium ions into every
25 hip implant patient's tissue and bloodstream. This is because cobalt-chromium metal
26 particles are released by friction from the metal femoral head rotating within the metal
27 liner. The particles then accumulate in the patient's tissue surrounding the implant giving
28

1 rise to metallosis, pseudotumors, trunnionosis, osteolysis, bone loss, and/or other
2 conditions.

3 36. The formation of trunnionosis, osteolysis, bone loss, metallosis,
4 pseudotumors, and infection and inflammation causes severe pain and discomfort, death
5 of surrounding tissue and bone loss, and lack of mobility.

6 37. The problems with Defendants' Accolade Hip Stem and LFIT Femoral Head
7 devices are similar to the issues that gave rise to Defendants' recall of the ASR XL
8 Acetabular System and ASR Hip Resurfacing System ("ASR"). Like the Defective
9 Devices, the ASR is also prone to early failure, and causes trunnionosis, osteolysis, bone
10 loss, metallosis, and cobalt and chromium toxicity resulting in serious health problems
11 and the need for subsequent revision surgery. As a result, Defendants, in acknowledging
12 the high failure rate of the ASR, recalled countless ASR devices worldwide. Defendants
13 also recalled the LFIT Femoral Heads for the same reasons.

14 38. On information and belief, Plaintiff alleges that many recipients of
15 Defendants' Defective Devices are suffering from elevated levels of chromium and
16 cobalt. Plaintiff further alleges on information and belief that Defendants are aware that
17 certain recipients of the Defective Devices have significantly elevated levels of
18 chromium and cobalt in amounts many times higher than acceptable or recommended
19 safety levels.

20 39. In January 2014, the Bone and Joint Journal published an article titled
21 *Raised Levels of Metal Ions in the Blood in Patients Who Have Undergone Uncemented*
22 *Metal-On-Metal Polyethylene Trident-Accolade Total Hip Replacement* finding high
23 concentrations of metal in the blood of patients that had an Accolade implanted in their
24 body.¹ The authors discontinued the use of the products and notified Defendants of the
25 results.

26
27
28

¹ Paul Craig, et al., *Raised Levels of Metal Ions in the Blood in Patients Who Have Undergone Uncemented Metal-On-Metal Polyethylene Trident-Accolade Total Hip Replacements*, 96-B BONE & JOINT J. 43, 43-47 (2004).

1 40. On information and belief, Defendants failed to notify patients of the results
2 of this study or dangers of their Defective Devices.

3 **E. Defendants' LFIT™ Anatomic V40™ Femoral Head Recall**

4 41. On or around August 29, 2016, Defendants recalled thousands of their LFIT
5 Femoral Heads. The recall cites gross trunnion failure, metal wear, adverse tissue
6 reaction and the need for revision surgery as causes for recalling the heads. Plaintiff
7 Ulrich suffered one and/or a combination of the above reactions resulting in the need to
8 surgically remove her Accolade TMZF Hip Stem and LFIT Anatomic LFIT Femoral
9 Head.

10 42. The recall notice states that Defendants are recalling certain lots of LFIT
11 V40 Femoral Heads as a result of several "Potential Hazards." The hazards identified
12 include, but are not limited to:

- 13 a. Disassociation of femoral head from hip stem
- 14 b. Fractured hip stem trunnion
- 15 c. Excessive metallic debris
- 16 d. Excessive wear debris

17 43. The recall notice further states that the problems caused by the LFIT™
18 Anatomic V40™ Femoral Head include "revision" surgery, "loss of mobility,"
19 "dislocation," "adverse local tissue reaction," and "periprosthetic fracture."

20 44. The recall notice fails to instruct surgeons to contact patients with the LFIT
21 Femoral Heads to undergo a simple, inexpensive blood test that can be used to determine
22 whether a patient is experiencing the corrosive process that can lead to catastrophic
23 failure. Specifically, the presence of elevated levels of cobalt, chromium, or titanium in
24 the blood is a definitive sign that a prosthetic hip is corroding.

25 45. Plaintiff is informed and believes, and thereon alleges, that the problems
26 with Defendants' Accolade Hip Stem and LFIT Femoral Head products are much larger
27 than those referenced in Defendants' recall notice. Plaintiffs allege that all LFIT™
28 Anatomic V40™ Femoral Heads sold by Defendants are defective and should be

1 recalled. Defendants have intentionally downplayed the risk of harm and limited the
2 scope of its recall in an effort to hide from surgeons, patients, and the FDA the true extent
3 of the problems with their defective hips.

4 **F. Plaintiff Joyce Ulrich’s Experience Illustrates a Tragic But Not Uncommon or**
5 **Unforeseeable Risk Associated with Defendants’ Defective Devices**

6 46. Defendants placed their Defective Devices into the stream of interstate
7 commerce and they were implanted in Plaintiff Joyce Ulrich on February 11, 2009.

8 47. On or about February 11, 2009, Plaintiff Joyce Ulrich, a then 68 year-old
9 female, had a right total hip replacement with the Stryker system, consisting of the
10 Accolade Hip Stem and LFIT Femoral Head.

11 48. After implantation of the Defective Devices, Plaintiff Joyce Ulrich began
12 experiencing discomfort and complications in her hip.

13 49. Due to elevated risk and instability in her right hip, Plaintiff underwent
14 revision surgery to her right hip on May 17, 2016.

15 50. During surgery, it was discovered that, in fact, there was significant
16 evidence of trunnionosis around the proximal femur at the junction between the head and
17 neck. The operative report also noted areas of osteolysis, bone loss, and loosening of the
18 femoral component. Once her surgeon removed the acetabulum, he noticed “a severe
19 amount of bone loss and osteolysis in the space behind the patient’s acetabular dome.”

20 51. Plaintiff has endured extensive rehabilitation since undergoing revision of
21 her right hip prosthesis.

22 52. Had Plaintiff Joyce Ulrich known that the Defective Devices caused pain,
23 swelling, inflammation, damage to the surrounding bone and tissue, problems walking,
24 and the need for revision surgery to replace the devices, she would not have elected to
25 have the Defective Devices implanted.

26 53. As a direct and proximate cause of the implantation of the Defective
27 Devices, Plaintiff Joyce Ulrich has suffered sufficient harm, including, but not limited to,
28 physical injury and bodily impairment, debilitating lack of mobility, and conscious pain

1 and suffering. In addition, because of the faulty nature of Defendants' products, Plaintiff
2 Joyce Ulrich endured severe pain and suffering.

3 54. As a result of the foregoing, Plaintiff Joyce Ulrich has suffered symptoms
4 including severe pain, swelling, inflammation and damage to surrounding bone and
5 tissue, including granulomatous, trunnionosis, and lack of mobility. These symptoms are
6 the result of possible loosening of the implant, where the bone around the implant may
7 have broken, dislocation, where the two parts of the implant that move against each other
8 are no longer aligned; or the spread of metal debris from the metal femoral head and
9 metal acetabulum cup rubbing and rotating against each other. For these reasons,
10 revisions surgery was necessary to remove the faulty Defective Devices from Plaintiff
11 Joyce Ulrich's right hip.

12 55. All of the injuries and complications suffered by Plaintiff Joyce Ulrich were
13 caused by the defective design, manufacturing defect, warnings, construction, and/or
14 unreasonably dangerous character of the Defective Devices that were implanted in her.
15 Had Defendants not concealed the known defects, the early failure rate, the known
16 complications, and the unreasonable risk associated with the use of the Defective
17 Devices, Plaintiff Joyce Ulrich and Plaintiff's healthcare providers would not have
18 consented to the Defective Devices being used in Plaintiff's total right hip arthroplasty
19 surgery. Had Plaintiff not been implanted with the Defective Devices, Plaintiff would
20 not have experienced the failure of her hip system, requiring her to have a premature
21 revision surgery.

22 56. The Defective Devices reached Plaintiff without substantial change in their
23 condition when they left the possession of Defendants and were used in the manner for
24 which they were intended. The Defective Devices were defective and unreasonably
25 dangerous when Defendants placed them into the stream of commerce.

26 57. Defendants continue to misrepresent the Defective Devices as high-quality,
27 safe and effective hip replacement products in their marketing and promotional materials.
28

1 This is despite the fact that Defendants have known for years that the Defective Devices
2 pose a danger to patients that have it implanted.

3 58. As a result, Defendants continue to sell the Defective Devices to doctors
4 who implant them in countless numbers of patients with an unreasonably high percentage
5 of those patients being forced to endure serious injury from trunnion, osteolysis, bone
6 loss, metallosis, pseudotumors, and biologic toxicity, among other complications. These
7 patients are reporting severe pain and discomfort and the need for one or more
8 complicated revision surgeries resulting in life-long health problems.

9 59. As a direct result of Defendants placing the Defective Devices into the
10 stream of commerce, Plaintiff Joyce Ulrich has suffered and continues to suffer both
11 injuries and damages, including but not limited to: past, present, and future physical and
12 mental pain and suffering; past, present, and future medical, hospital, rehabilitative, and
13 pharmaceutical expenses, and other related damages.

14 60. Plaintiff Joyce Ulrich was unaware of any causal link between the injuries
15 she has suffered and any wrongdoing on the part of Defendants due to the faulty and
16 defective nature of the Defective Devices, due in part to the failures of Defendants to
17 properly warn her and her physicians about the Defective Devices and their faulty nature.
18 In and around August 2016, Plaintiff Joyce Ulrich first became aware of a causal link
19 when Defendants released an urgent recall notice. Plaintiff was unable to make an earlier
20 discovery of a causal link despite reasonable diligence because of Defendants' failure to
21 properly warn her and her physicians about Defendants' Defective Devices, their faulty
22 nature, and Defendants' failure to issue a timely recall or take any other proactive action
23 with respect to the injuries being caused to patients that have been implanted with the
24 Defective Devices.

25 61. Plaintiff exercised reasonable diligence in investigating potential causes of
26 her injury by discussing her injuries with healthcare providers. None of Plaintiff's
27 conversations with her healthcare providers gave Plaintiff any reason to suspect, or
28 reasonably should have given Plaintiff a reason to suspect, that the hip implant was

1 defective. Under the facts of this case, Plaintiff's suit was filed well within the applicable
2 statute of limitations period.

3 62. Defendants fraudulently concealed relevant facts from Plaintiff and the
4 medical community about the true risks of harm associated with its Defective Devices
5 and fraudulently advised the medical community that instances of corrosion were non-
6 existent and/or extremely rare. As a result, Plaintiff, Plaintiff's physicians, nurses, and/or
7 healthcare staff were deprived of vital information essential to the pursuit of these claims,
8 without any fault or lack of diligence on their part.

9 63. At all times relevant, Plaintiff, Plaintiff's physicians, nurses, and/or
10 healthcare staff relied on Defendants' misrepresentations and omissions and therefore
11 could not reasonably have known or become aware of facts that would lead a reasonable,
12 prudent person to make an inquiry to discover Defendants' tortious conduct. Plaintiff
13 diligently filed suit once she discovered the actual facts that would lead a reasonable,
14 prudent person to make an inquiry to discover Defendants' tortious conduct. Defendants'
15 misconduct and fraudulent concealment of relevant facts, as described above, tolls any
16 relevant statute of limitations. Regardless, Plaintiff's suit is filed well within the
17 applicable statutory limitations period.

18 64. Defendants are and were under a continuing duty to monitor and disclose the
19 true character, quality, and nature of its Defective Devices. Because of Defendants'
20 misconduct and fraudulent concealment of the true character, quality, and nature of its
21 devices, Defendants are estopped from relying on any statute of limitations defense.
22

23 **V. CAUSES OF ACTION**
24 **FIRST CAUSE OF ACTION**
25 **NEGLIGENCE**
26

27 65. Plaintiff incorporates, by reference, as if fully set forth herein, each and
28 every allegation set forth in the preceding paragraphs and further alleges as follows.

1 66. Defendants designed, manufactured, marketed, distributed, and/or advertised
2 both the Accolade Hip Stem and LFIT Femoral head to physicians and consumers.

3 67. Defendants had a duty to exercise reasonable care in the design,
4 manufacture, testing, marketing, and distribution into the stream of commerce of the
5 Defective Devices, including a duty to insure that the Defective Devices did not pose a
6 significant risk of adverse events.

7 68. Defendants failed to exercise reasonable care in designing, manufacturing,
8 testing, marketing, and distributing the Defective Devices into the stream of commerce.
9 Defendants knew or should have known that the Defective Devices could fail early in
10 patients, therefore giving rise to pain and suffering, debilitation, and the need for a
11 revision surgery to replace the device with the attendant risks of complications and death
12 from such further surgery, and therefore were not safe for use by Plaintiff Joyce Ulrich.

13 69. Despite the fact that Defendants knew or should have known that the
14 Defective Devices could fail early in patients, therefore giving rise to pain and suffering,
15 debilitation, and the need for revision surgeries to replace the device with the attendant
16 risks of complications and death from such further surgeries, Defendants continued to
17 market the Defective Devices as a safe and effective hip replacement system.

18 70. As a direct and proximate result of Defendants' negligence, Plaintiff has
19 suffered significant damages, including but not limited to physical injury, economic loss,
20 pain and suffering, and the need for further surgeries to replace the faulty devices, and
21 will continue to suffer such damages in the future.

22 71. In performing the foregoing acts and omissions, Defendants acted
23 despicably, fraudulently, and with malice and oppression so as to justify an award of
24 punitive and exemplary damages.

25 ///

26 ///

27 ///

28 ///

1 **SECOND CAUSE OF ACTION**

2 **STRICT PRODUCTS LIABILITY (MANUFACTURING DEFECT)**

3
4 72. Plaintiff incorporates, by reference, as if fully set forth herein, each and
5 every allegation set forth in the preceding paragraphs and further alleges as follows.

6 73. Defendants designed, manufactured, tested, marketed, and distributed into
7 the stream of commerce the Defective Devices.

8 74. The Defective Devices that were surgically implanted in Plaintiff Joyce
9 Ulrich were defective in their manufacture when the devices left the hands of Defendants
10 in that they deviated from product specifications, posing a serious risk that they could fail
11 early in patients therefore giving rise to physical injury, pain and suffering, deliberation,
12 and the need for revision surgeries to replace the devices with the attendant risks of
13 complications and death from such further surgeries.

14 75. As a direct and proximate result of Defendants' placement of the Defective
15 Devices into the stream of commerce, Plaintiff has suffered significant damages,
16 including but not limited to physical injury, economic loss, pain and suffering, and the
17 need for further surgery to replace the faulty devices, and will continue to suffer such
18 damages in the future.

19 **THIRD CAUSE OF ACTION**

20 **STRICT PRODUCTS LIABILITY (DESIGN DEFECT)**

21
22 76. Plaintiff incorporates, by reference, as if fully set forth herein, each and
23 every allegation set forth in the preceding paragraphs and further alleges as follows.

24 77. Defendants designed, manufactured, tested, marketed, and distributed into
25 the stream of commerce the Defective Devices.

26 78. The Defective Devices that were surgically implanted in Plaintiff Joyce
27 Ulrich were defective in their design when they left the hands of Defendants in that the
28 design was flawed, thereby posing a serious risk that the devices could fail early in

1 patients, giving rise to physical injury, pain and suffering, debilitation, and the need for
2 revision surgeries to replace the devices with the attendant risks of complications and
3 death from such further surgeries.

4 79. As a direct and proximate result of Defendants' placement of the Defective
5 Devices into the stream of commerce, Plaintiff has suffered significant damages,
6 including but not limited to physical injury, economic loss, pain and suffering, and the
7 need for further surgeries to replace the faulty devices, and will continue to suffer such
8 damages in the future.

9 **FOURTH CAUSE OF ACTION**

10 **STRICT PRODUCTS LIABILITY (INADEQUATE WARNING)**

11
12 80. Plaintiff incorporates, by reference, as if fully set forth herein, each and
13 every allegation set forth in the preceding paragraphs and further alleges as follows.

14 81. Defendants designed, manufactured, tested, marketed, and distributed into
15 the stream of commerce the Defective Devices.

16 82. The Defective Devices that were surgically implanted in Plaintiff Joyce
17 Ulrich were defective due to inadequate warning because Defendants knew or should
18 have known that the Defective Devices could fail early in patients, therefore giving rise
19 to physical injury, pain and suffering, debilitation, and the need for revision surgeries to
20 replace the devices with the attendant risks of complications and death from such further
21 surgeries, but failed to give consumers adequate warning of such risk. Further, the
22 Defective Devices placed into the stream of commerce by Defendants were surgically
23 implanted in a manner reasonably anticipated by Defendants.

24 83. As a direct and proximate result of Defendants' placement of the Defective
25 Devices into the stream of commerce, Plaintiff has suffered significant damages,
26 including but not limited to physical injury, economic loss, pain and suffering, and the
27 need for further surgeries to replace the faulty devices, and will continue to suffer such
28 damages in the future.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

FIFTH CAUSE OF ACTION
STRICT PRODUCTS LIABILITY (FAILURE TO CONFORM TO
REPRESENTATIONS)

84. Plaintiff incorporates, by reference, as if fully set forth herein, each and every allegation set forth in the preceding paragraphs and further alleges as follows.

85. Defendants designed, manufactured, tested, marketed, and distributed into the stream of commerce the Defective Devices.

86. Defendants made representations to consumers regarding the character or quality of the Defective Devices, including, but not limited to, statements that Stryker hip implant devices were safe and effective hip replacement systems.

87. Defendants' Accolade Hip Stem and LFIT Femoral Head products were placed into the stream of commerce and were defective when they left the hands of Defendants and they did not conform to Defendants' representations.

88. Plaintiff Joyce Ulrich justifiably relied upon Defendants' representations regarding the Defective Devices.

89. As a direct and proximate result of Defendants' placement of the Defective Devices into the stream of commerce, Plaintiff has suffered significant damages, including but not limited to physical injury, economic loss, pain and suffering, and the need for further surgeries to replace the faulty devices, and will continue to suffer such damages in the future.

25
26
27
28

SIXTH CAUSE OF ACTION
STRICT PRODUCTS LIABILITY (FAILURE TO ADEQUATELY TEST)

90. Plaintiff incorporates, by reference, as if fully set forth herein, each and every allegation set forth in the preceding paragraphs and further alleges as follows.

91. Defendants designed, manufactured, tested, marketed, and distributed into the stream of commerce the Defective Devices.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

NINTH CAUSE OF ACTION
NEGLIGENT MISREPRESENTATION

106. Plaintiff incorporates, by reference, as if fully set forth herein, each and every allegation set forth in the preceding paragraphs and further alleges as follows.

107. Defendants supplied false information to the public, to Plaintiff and to her physicians regarding the high-quality, safety and effectiveness of the Defective Devices. Defendants provided this false information to induce the public, Plaintiff, and her physicians to purchase and implant the Defective Devices.

108. Defendants knew or should have known that the information they supplied regarding the purported high-quality, safety and effectiveness of the implant was provided to induce Plaintiff and her physicians to purchase and use the Defective Devices and was false.

109. Defendants were negligent in obtaining or communicating false information regarding the purported high-quality, safety and effectiveness of the Defective Devices.

110. Plaintiff and her physicians relied on false information supplied by Defendants to their detriment by causing the Defective Devices to be purchased and implanted in Plaintiff.

111. Plaintiff and her physicians were justified in their reliance on false information supplied by Defendants regarding the purported high-quality, safety and effectiveness of the Defective Devices.

112. As a direct and proximate result of Defendants' placement of the defective Stryker hip implant device into the stream of commerce, Plaintiff has suffered significant damages, including but not limited to physical injury, economic loss, pain and suffering, and the need for further surgeries to replace the faulty devices, and will continue to suffer such damages in the future.

///

///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TENTH CAUSE OF ACTION
FRAUD

113. Plaintiff incorporates, by reference, as if fully set forth herein, each and every allegation set forth in the preceding paragraphs and further alleges as follows.

114. Defendants made representations to Plaintiff and her physicians that their Stryker device was a high-quality, safe and effective hip replacement system.

115. Before they marketed the Defective Devices that were implanted in Plaintiff, Defendants knew or should have known of the unreasonable dangers and serious health risks that such a total hip replacement system posed to patients like Plaintiff.

116. As specifically described in detail above, Defendants knew that the Defective Devices subjected patients to early failure, painful and harmful physical reaction to toxic metallic particles and ions, death of tissue, bone loss, dislocations, and the need for explants and revision surgery.

117. Defendants' representations to Plaintiff and her physicians that their Defective Devices are high-quality, safe and effective were false.

118. Defendants concealed their knowledge of the unreasonable risks and dangers associated with the use of the Stryker device to induce Plaintiff and many thousands of others to purchase the system for surgical implantation in their bodies.

119. Neither Plaintiff nor her physicians knew of the falsity of Defendants' statements regarding the Stryker device.

120. Plaintiff and her physicians relied upon and accepted as truthful Defendants' representations regarding the Stryker device.

121. As a direct and proximate result of Defendants' placement of the defective Stryker hip implant device into the stream of commerce, Plaintiff has suffered significant damages, including but not limited to physical injury, economic loss, pain and suffering, and the need for further surgeries to replace the faulty devices, and will continue to suffer such damages in the future.

1
2
3
4
5
6
7
8
9
10
11
12
13
14

**ELEVENTH CAUSE OF ACTION
PUNITIVE DAMAGES**

122. Plaintiff incorporates, by reference, as if fully set forth herein, each and every allegation set forth in the preceding paragraphs and further alleges as follows.

123. Defendants' conduct in marketing, advertising, promoting, manufacturing, distributing, and/or selling the Accolade Hip Stem and LFIT Femoral Heads constitutes gross negligence, reckless, and intentional misconduct as to warrant the award of punitive damages to punish Defendants and to deter Defendants and others from like conduct in the future.

124. In performing the foregoing acts and omissions, Defendants acted despicably, fraudulently, and with malice and oppression as to justify an award of punitive and exemplary damages.

15
16
17
18
19
20
21
22
23
24
25
26
27
28

VI. PRAYER FOR RELIEF

Wherefore, Plaintiff Joyce Ulrich prays for the following relief:

- A. Judgement in favor of Plaintiff and against all Defendants, for damages in such amounts as may be proven at trial;
- B. Award all actual, general, special, incidental, statutory, punitive, and consequential damages and restitution to which Plaintiff is entitled;
- C. Compensation for both economic and non-economic losses, including but not limited to medical expenses, loss of earnings, loss of consortium, disfigurement, pain and suffering, mental anguish, and emotional distress, in such amounts as may be proven at trial;
- D. Punitive and/or exemplary damages in such amounts as may be proven at trial;
- E. Pre-judgement and post-judgement interest on such monetary relief;
- F. Reasonable attorneys' fees and costs; and

1 G. Any and all further relief, both legal and equitable, that the Court may deem
2 just and proper.

3 **VII. DEMAND FOR JURY TRIAL**

4 Plaintiff demands a trial by jury on all issues so triable.
5

6
7 DATED: June 5, 2017

MCCUNE WRIGHT AREVALO, LLP

8
9 BY: /s/ Kristy M. Arevalo

Kristy M. Arevalo

Tuan Q. Nguyen
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28